
Professor Rod Hicks
Professor Rod Hicks, Melbourne Theranostic Innovation Centre, Professorial Fellow, The University of Melbourne and Adjunct Professor, Monash University
Speaker's biography
Rod is a Professor of Medicine at the University of Melbourne and at Monash University. He was the inaugural Director of Cancer Imaging at the Peter MacCallum Cancer Centre and is an internationally-recognized pioneer in oncological PET and therapeutic nuclear medicine with more than 30-years’ experience in both. He has recently founded a company to perform research and development into the emerging field of theranostics and has installed an ultraextended-field-of-view PET/CT scanner at the Melbourne Theranostic Innovation Centre (MTIC) in Melbourne.
He was inducted as a Fellow of the Australian Academy of Health and Medical Science in 2015 and was the recipient of the 2019 International Cancer Imaging Society Gold Medal for contributions to oncological imaging and 2021 Peter E. Valk Memorial Award of the Society of Nuclear Medicine for lifetime achievements
in clinical PET. In 2023, he received the Saul Hertz Award from the Society of Nuclear Medicine for his contribution to the field of theranostics. He was also awarded an Order of Australia Membership (AM) in the General Division in the King’s Birthday Honours of 2023.
He has published over 700 peer-reviewed manuscripts including contributions in the New England Journal of Medicine, Journal of Clinical Oncology, the Lancet, Lancet Oncology, Clinical Cancer Research, Nature Reviews Clinical Oncology, Nature Communications, and the Journal of Nuclear Medicine. His H-index is over 100 with over 43,000 lifetime citations (Google Scholar).
Professor Hicks ran the Translational Research Laboratory and Pre-Clinical Imaging Facility at the Peter MacCallum Cancer Centre from 2002-2021 and has a strong research interest in the linking of genotype with molecular imaging phenotype and personalized selection and delivery of radionuclide therapy, including combinatorial therapies. He has been actively involved in developing and clinically implementing novel radiopharmaceuticals for diagnostic and therapeutic applications.